cytarabine and Granulocytic Leukemia, Chronic

cytarabine has been researched along with Granulocytic Leukemia, Chronic in 308 studies

Research

Studies (308)

Timeframe	Studies, this research(%)	All Research%
pre-1990	16 (5.19)	18.7374
1990's	125 (40.58)	18.2507
2000's	129 (41.88)	29.6817
2010's	33 (10.71)	24.3611
2020's	5 (1.62)	2.80

Authors

Authors	Studies
Cao, J; Chen, Y; Dong, QF; Hu, JD; Li, F; Luo, LT; Sang, YQ; Wang, J; Wang, SL; Yang, T; Ye, YZ; Zhang, L; Zheng, J; Zheng, XY	1
Iriyama, N; Kawaguchi, T; Kirito, K; Kizaki, M; Shimoda, K; Takahashi, N	1
Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W	1
Gangat, N; Tefferi, A	1
Alexis, M; Arkam, Y; Berger, M; Berthou, C; Bulabois, CE; Caillot, D; Cambier, N; Cayuela, JM; Chapiro, J; Charbonnier, A; Chomel, JC; Coiteux, V; Cony-Makhoul, P; Deconinck, E; Delmer, A; Delord, M; Dorvaux, V; Dubruille, V; Escoffre Barbe, M; Etienne, G; Fouillard, L; Gardembas, M; Ghomari, K; Glaisner, S; Guerci-Bresler, AP; Guilhot, F; Guilhot, J; Gyan, E; Johnson-Ansah, H; Joly, B; Jourdan, E; Kiladjian, JJ; Lebon, D; Legros, L; Lenain, P; Lhermitte, L; Mahon, FX; Maisonneuve, H; Maloisel, F; Mercier, M; Miclea, JM; Muller, M; Nicolini, FE; Penot, A; Plantier, I; Pollet, B; Preudhomme, C; Rea, D; Rigal-Huguet, F; Rousselot, P; Roy, L; Santagostino, A; Vaida, I; Vekhoff, A; Zerazhi, H	1
Moyo, TK; Savona, MR	1
Messina, J; Nethers, K; Seminario-Vidal, L	1
Dağlı, M; Keles Oğlu, KS; Koplay, M; Paksoy, Y; Sivri, M	1
Kállay, K; Kassa, C; Kertész, G; Kriván, G; Reményi, P; Sinkó, J	1
Chen, B; Chen, D; Guan, C; Peng, M; Shao, X; Xie, P; Xu, P; Yuan, C	1
Cardarelli, L; Chiaretti, S; Diverio, D; Foà, R; Giona, F; Mancini, F; Miano, M; Moleti, ML; Nanni, M; Palumbo, G; Peragine, N; Santopietro, M; Testi, AM; Zhang, K	1
Abruzzo, L; Borthakur, G; Cortes, J; Faderl, S; Jabbour, E; Jorgensen, JL; Kantarjian, H; Konoplev, S; Luthra, R; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Strati, P; Thomas, D	1
Baerlocher, GM; Dengler, J; Ehninger, G; Einsele, H; Fabarius, A; Falge, C; Haferlach, C; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Heimpel, H; Hochhaus, A; Hossfeld, DK; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Nerl, C; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Pletsch, N; Proetel, U; Saußele, S; Schnittger, S; Schreiber, A; Spiekermann, K; Stegelmann, F; Waller, CF	1
Chen, H; Chen, J; Du, G; Han, Q; Liu, C; Sun, M; Wang, W; Wu, L	1
He, Y; Hu, Y; Li, XD; Lin, DJ; Wang, DN; Wang, WW; Xiao, RZ	1
Akhtari, M; Armitage, JO; Bhatt, VR; Bociek, RG; Dave, BJ; Kessinger, A; Sanger, WG; Sanmann, JN; Yuan, J	1
Audemard, A; Bergot, E; Chantepie, S; de la Gastine, B; Gac, AC; Reman, O; Verger, H	1
Cachia, D; Chi, L; Cortes, JE; Daver, N; Kamiya-Matsuoka, C; Kantarjian, HM; Pinnix, CC; Woodman, K	1
Asano, S; Ishii, H; Kato, S; Konuma, T; Oiwa-Monna, M; Takahashi, S; Tojo, A	1
Bartholomäus, A; Bentz, M; Berdel, WE; Burchert, A; de Wit, M; Eckart, MJ; Fabarius, A; Gassmann, W; Hahn, M; Hanfstein, B; Hasford, J; Hebart, HF; Hehlmann, R; Heim, D; Heymanns, J; Hochhaus, A; Hofmann, WK; Kalmanti, L; Kraemer, D; Krause, SW; Krauss, MP; Lauseker, M; Leibundgut, EO; Müller, MC; Pezzutto, A; Pfirrmann, M; Proetel, U; Saussele, S; Schmidt-Wolf, I; Schmitz, N; Staib, P; Wernli, M; Zettl, F	1
Alousi, A; Anderlini, P; Andersson, BS; Borthakur, G; Bueso-Ramos, C; Champlin, RE; Chen, J; Ciurea, SO; El Fakih, R; Gaballa, S; Garcia-Manero, G; Hosing, C; Jimenez, A; Kantarjian, H; Kebriaei, P; Khouri, IF; Kongtim, P; Marin, D; Oran, B; Pemmaraju, N; Popat, U; Rezvani, K; Rondon, G; Shpall, EJ	1
Non, LR; Pande, A; Romee, R; Santos, CA	1
Baccarani, M; Branford, S; Cervantes, F; Deininger, MW; Druker, BJ; Fujihara, S; Guilhot, F; Hochhaus, A; Hughes, TP; Kantarjian, H; Larson, RA; Menssen, HD; O'Brien, SG; Ortmann, CE; Radich, JP	1
Bloomfield, CD; Deangelo, DJ; Donohue, KA; Hars, V; Larson, RA; Linker, CA; Marcucci, G; Shea, T; Stock, W; Stone, RM	1
Assa'ad, A; Burns, K; Hershey, GK; Johnson, T; Lierl, MB; Metz, KA; Seidu, L	1
Ayuk, F; Bacher, U; Brümmendorf, TH; Fiedler, W; Hochhaus, A; Iwanski, GB; Klyuchnikov, E; Kröger, N; Ocheni, S; Schafhausen, P; Schnittger, S; Zabelina, T; Zander, AR	1
Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S	1
Druker, B; Gathmann, I; Guilhot, F; Larson, RA; O'Brien, SG; So, C; Waltzman, R	1
Berendse, HW; Janssen, JJ; Merle, PA; Ossenkoppele, GJ; Schuurhuis, GJ	1
Hackanson, B; Lübbert, M; Rückert, A	1
Ozawa, K	1
Arnold, R; Beelen, DW; Bunjes, D; Dengler, R; Falge, C; Gratwohl, A; Haferlach, C; Hasford, J; Hehlmann, R; Ho, AD; Hochhaus, A; Holler, E; Kanz, L; Kolb, HJ; Lauseker, M; Leitner, A; Müller, MC; Pfirrmann, M; Pletsch, N; Saussele, S; Schlegelberger, B; Schlimok, G; Schnittger, S; Schwerdtfeger, R; Zander, AR	1
Beverloo, HB; Cornelissen, JJ; Daenen, SM; Deenik, W; Ferrant, A; Janssen, JJ; Kersten, MJ; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Smit, WM; Sonneveld, P; Valk, PJ; van der Holt, B; van Marwijk Kooy, M; Verdonck, LF; Verhoef, GE; Wijermans, PW; Willemze, R; Wittebol, S	1
Arslan, M; Erkut, M; Erkut, N; Ersoz, S; Sonmez, M	1
Ohno, R	1
Gui-Nan, L; Guo-Bao, W; Jie, L; Qi-Rong, G; Xiao-Qin, C; Yue, L	1
Hirao, A; Hoshii, T; Naka, K	1
Berthou, C; Castaigne, S; Cayuela, JM; Cony-Makhoul, P; Deau, B; Gardembas, M; Guerci, A; Guilhot, F; Guilhot, J; Guyotat, D; Hayette, S; Huguet, F; Legros, L; Mahon, FX; Michallet, M; Nicolini, FE; Pautas, C; Réa, D; Rousselot, P; Weiss, IR	1
Barbagallo, I; Chiarenza, A; Conticello, C; Del Fabro, V; Di Raimondo, F; Giallongo, C; La Cava, P; Palumbo, GA; Parrinello, N; Romano, A; Stagno, F; Tibullo, D	1
Fujisaki, T; Moriyama, Y; Muta, T; Sawada, Y; Seike, Y; Tokuyama, T; Ueda, Y	1
Crawley, C; Follows, G; Sarkies, N; Tziotzios, C	1
Chen, X; Yang, W; Zhu, X	1
Apperley, J; Foroni, L; Ibrahim, A; Marin, D; Milojkovic, D; Reid, A	1
Baerlocher, GM; Branford, S; Dengler, J; Einsele, H; Erben, P; Fabarius, A; Falge, C; Göhring, G; Haferlach, C; Hänel, M; Hanfstein, B; Hasford, J; Hehlmann, R; Hochhaus, A; Hofmann, WK; Hughes, TP; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saußele, S; Schnittger, S; Schubert, J; Spiekermann, K; Stegelmann, F; Waller, CF	1
Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F	1
Caruso, M; de Campos-Lima, PO; Ghani, K; Naud, JS	1
Bowen, DT; Durairaj, S; Groves, MJ; Hyslop, A; Keenan, N; Tauro, S	1
Beran, M; Dong, L; Kantarjian, HM; Keating, MJ; Onida, F; Scappini, B; Verstovsek, S	1
Axdorph, U; Björkholm, M; Carneskog, J; Grimfors, G; Hansen, J; Linder, O; Ljungman, P; Löfvenberg, E; Malm, C; Simonsson, B; Stenke, L; Turesson, I; Udén, AM; Vilén, L	1
Bilhou-Nabera, C; Blaise, D; Boiron, JM; Boucheix, C; Bourhis, JH; Buzyn, A; Cayuela, JM; Charrin, C; Delannoy, A; Dombret, H; Espérou, H; Fegueux, N; Fenaux, P; Fière, D; Gabert, J; Lhéritier, V; MacIntyre, E; Rigal-Huguet, F; Thomas, X; Vernant, JP	1
Ayyildiz, O; Bolaman, Z; Demir, S; Kadiköylü, G; Köseoğlu, M; Müftüoğlu, E; Sönmez, HM	1
Chen, Q; Du, QF; Li, R; Liu, QF; Liu, XL; Zhou, SY	1
Bali, P; Bhalla, K; Burnette, PK; Huang, M; Jove, R; Loughran, T; Nimmanapalli, R; O'Bryan, E; Tepperberg, J	1
Dewald, GW; Lesser, ML; Silver, RT; Sison, CP	1
Al-Ali, HK; Bumm, T; Deininger, MW; Franke, C; Friedrich, T; Hennig, E; Krahl, R; Krohn, K; Leiblein, S; Müller, C; Niederwieser, D; Schmidt, E; Shepherd, P	1
Hansz, J	1
Hentrich, M; Ledderose, G; Salat, C; Stoetzer, OJ	1
Hentrich, M; Salat, C; Stoetzer, OJ	1
Galetta, SL; Massaro-Giordano, M; Schocket, LS; Volpe, NJ	1
Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA	1
Baccarani, M; Bassi, S; Bonifazi, F; De Vivo, A; Martinelli, G; Rosti, G; Russo, D; Testoni, N; Trabacchi, E	1
Baron, F; Beguin, Y; Fillet, G; Hafraoui, K; Humblet-Baron, S	1
Abgrall, JF; Berthou, C; Braekeleer, MD; Bris, MJ; Calvez, GL; Herry, A; Marion, V; Morel, F	1
Robak, T	1
Bloomfield, CD; Carroll, AJ; Larson, RA; Peterson, BL; Powell, BL; Schiffer, CA; Silver, RT; Stock, W; Szatrowski, TP	1
Brandwein, J; Gupta, V; Kamel-Reid, S; Lipton, JH; Messner, HA; Minden, MD	1
Breitenbuecher, F; Carius, B; Fischer, T; Gschaidmeier, H; Huber, C; Kasper, S; Kindler, T; Stevens, T	1
Glendenning, GA; Hahn, EA	1
Deininger, MW; O'Brien, SG	1
Berthaud, P; Berthou, C; Buzyn, A; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Najman, A; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M	1
Beth Rios, M; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Shan, J; Talpaz, M; Thomas, D; Verstovsek, S; Wierda, W	1
Dokekias, AE; Malanda, F; Mbalawa, ChG	1
Berthaud, P; Berthou, C; Buzyn, A; Cheron, N; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M	1
Andreeff, M; Cortes, J; Faderl, S; Freireich, E; Garcia-Manero, G; Giles, F; Kantarjian, HM; Kornblau, S; Mallard, S; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D; White, K	1
Hada, Y; Horio, T; Kaminishi, Y; Katsuma, S; Ohgi, T; Takagaki, K; Tanaka, T; Yano, J	1
Agis, H; Geissler, K; Mannhalter, C; Mayerhofer, M; Sagaster, V; Sillaber, C; Sperr, WR; Valent, P	1
Arthur, C; Bradstock, K; Branford, S; Browett, P; Durrant, S; Gathmann, I; Grigg, A; Harper, A; Hughes, TP; Joske, D; Lynch, K; Ma, D; Rudzki, Z; Schwarer, AP; Seymour, JF; Taylor, K	1
Aulitzky, W; Berger, U; Berndt, A; Deininger, MW; Fischer, T; Freund, M; Fruehauf, S; Gattermann, N; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Hossfeld, DK; König, H; Krause, SW; Kreil, S; Lahaye, T; le Coutre, P; Merx, K; Müller, MC; Nerl, C; Neubauer, A; Ottmann, OG; Paschka, P; Sayer, HG; Schneller, F; Waller, C	1
Löwenberg, B	1
Bolton, AE; Branford, S; Gathmann, I; Goldman, JM; Hensley, ML; Hochhaus, A; Hughes, TP; Kaeda, J; Radich, JP; Rudzki, Z; van Hoomissen, IC	1
Berger, U; Hehlmann, R	1
Giakoumi, X; Mantzouranis, M; Pangalis, GA; Vassilakopoulos, TP; Viniou, NA	1
Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T	1
Ueda, T	1
Ascani, S; Bonomini, S; Caramatti, C; Colla, S; Craviotto, L; Crugnola, M; De Celis, I; Giuliani, N; Hojden, M; Morandi, F; Rizzoli, V; Sabbatini, E; Sammarelli, G	1
Bujassoum, S; Lipton, JH; Rifkind, J	1
Borthakur, G; Cortes, JE	1
Alcalá, A; Besses, C; Boqué, C; Camós, M; Cervantes, F; Sureda, A	1
Buesche, G; Buhr, T; Fonatsch, C; Freund, M; Ganser, A; Georgii, A; Hasford, J; Hecker, H; Hehlmann, R; Heimpel, H; Heinze, B; Holgado, S; Kreipe, HH; Pfirrmann, M; Schmeil, A; Tobler, A	1
Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C	1
Allen, AS; Anstrom, KJ; Glendenning, GA; Reed, SD; Schulman, KA	1
Anstrom, KJ; Glendenning, GA; Ludmer, JA; Reed, SD; Schulman, KA	1
Fricová, M; Guman, T; Hlebasková, M; Kafková, A; Rraffac, S; Stecová, N; Svorcová, E; Tóthová, E	1
Cortes, J; Dewald, GW; Kantarjian, HM; Litzow, ML; Mauro, MJ; Talpaz, M; Tefferi, A	1
Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L	1
Raghunadharao, D; Rajappa, S; Rao, IS; Surath, A; Uppin, SG	1
Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S	1
Bousquet, M; Brousset, P; Dastugue, N; De Mas, V; Delsol, G; Duchayne, E; Laurent, G; Quelen, C; Roquefeuil, B	1
Cortes, J; Fettner, S; Hooftman, L; Kantarjian, H; O'Brien, S; Rakhit, A; Rittweger, K; Talpaz, M	1
Fay, M; Goldman, J; Murphy, PT; O'Donnell, R; Quinn, J; Swords, R	1
Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B	1
Clapisson, G; Hayette, S; Michallet, M; Nicolini, FE; Philip, I; Prebet, T; Tigaud, I	1
Fiser, K; Klamová, H; Moravcová, J	1
Berman, E; Bhalla, K; Copelan, EA; Devetten, MP; Emanuel, PD; Erba, HP; Greenberg, PL; Moore, JO; O'Brien, S; Przepiorka, D; Radich, JP; Schilder, RJ; Shami, P; Smith, BD; Snyder, DS; Soiffer, RJ; Tallman, MS; Talpaz, M; Wetzler, M	1
Béhard, C; Berger, C; Bernard, F; Cornu, G; Duchène, S; Gandemer, V; Guilhot, F; Guilhot, J; Leblanc, T; Leverger, G; Millot, F; Nelken, B	1
Owen-Lynch, PJ; Pierce, A; Thompson, SE; Underhill-Day, N; Whetton, AD; Xenaki, D	1
Hong-eng, S; Limsuwan, A; Pakakasama, S; Rochanawutanon, M	1
Adamczyk-Cioch, M; Dmoszyńska, A; Haus, O; Hołowiecki, J; Jakubas, B; Jedrzejczak, WW; Konopka, L; Kuliczkowski, K; Mazur, G; Nowak, K; Paluszewska, M; Pałynyczko, G; Pluta, A; Robak, T; Skotnicki, A; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A; Zwolińska, M	1
Bloomfield, CD; Karrison, T; Larson, RA; Sher, D; Stock, W; Stone, RM; Yu, D	1
Druker, BJ; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Krahnke, T; Larson, RA; Massimini, G; O'Brien, S; Roy, L; So, C	1
Heim, D	1
Urabe, A	2
Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B	1
Antonenko, EV; Cherepovich, VS; Grinëv, VV; Lotkova, ES; Shakhlevich, EV	1
Agis, H; Baccarani, M; Cervantes, F; Cornelissen, JJ; Deininger, MW; Druker, BJ; Fischer, T; Gabrilove, JL; Gathmann, I; Gattermann, N; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Hughes, T; Kantarjian, H; Larson, RA; Letvak, L; Nielsen, JL; O'Brien, SG; Powell, BL; Radich, JP; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Silver, RT; Simonsson, B; So, C; Stone, RM; Taylor, K; Verhoef, G	1
Altintas, A; Ayyildiz, O; Cil, T; Kaplan, MA; Kilinc, I	1
Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Wierda, W	1
Carella, AM	1
Balleisen, L; Buss, EC; Emmerich, B; Fischer, T; Fruehauf, S; Hehlmann, R; Ho, AD; Hochhaus, A; Müller, MC; Ottmann, OG; Schuld, P; Topaly, J	1
Barbu, V; Carbonne, B; Garderet, L; Gorin, NC; Santacruz, R; van den Akker, J	1
Ishizawa, K	1
Lenhart, S; Moore, H; Nanda, S	1
Agis, H; Aichberger, KJ; Esterbauer, H; Haas, OA; Herndlhofer, S; Jäger, U; Knöbl, P; Rabitsch, W; Schwarzinger, I; Sillaber, C; Sperr, WR; Thalhammer, R; Valent, P	1
Chang, HJ; Cho, MS; Choi, MY; Kong, JH; Kwon, JM; Lee, KE; Lee, SM; Lee, SN; Mun, YC; Nam, E; Nam, SH; Seong, CM; Yoo, SH	1
Beverloo, HB; Cornelissen, JJ; Deenik, W; Ferrant, A; Janssen, JJ; Kersten, MJ; Kluin-Nelemans, HC; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Smit, WM; Sonneveld, P; Valk, P; van der Holt, B; van Marwijk Kooy, M; Verdonck, LF; Verhoef, GE; Westveer, PH; Wijermans, PW; Willemze, R; Wittebol, S	1
Delaney, SM; Dolan, ME; Gajria, D; Karrison, TG; Larson, RA; Odenike, OM; Ratain, MJ; Stock, W	1
Kouides, PA; Rowe, JM	1
Fujita, J; Maruyama, Y; Ogawa, K; Okuma, M; Sawada, H; Sawai, H; Tashima, M; Toi, T	1
Bergamaschi, G; Carella, AM; Cazzola, M; Ferrero, R; Podestá, M; Pollicardo, N; Pungolino, E; Raffo, MR; Rosti, V; Saglio, G	1
Lemoli, RM; Manfroi, S; Pelliconi, S; Rosti, G; Testoni, N; Tosi, P; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL	1
Carella, AM; Ferrero, R; Frassoni, F; Podestá, M; Pollicardo, N; Pungolino, E; Soracco, M	1
Scheinberg, DA	1
Bernasconi, P; Betti, AR; Caricchi, P; Donti, E; Ferrajoli, A; Lazzarino, M; Liberati, AM; Morra, E; Saglio, G	1
Catapano, CV; Colombo, T; Conter, V; Damia, G; Gervasoni, M; Giudici, G; Limonta, M; Liso, V; Masera, G; Specchia, G	1
Carella, AM; Frassoni, F; Parodi, C; Podesta, M; Pollicardo, N; Pungolino, E; Rabitti, C; Raffo, MR; Sessarego, M; Vimercati, R	1
Chalmers, EA; Clarke, R; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, S; Sharp, S; Sproul, AM; Tansey, P; Watson, W	1
Chorvath, B; Duraj, J; Hunakova, L; Novotny, L; Sedlak, J	1
Lot, TY; Onwukeme, KE	1
Calvert, L; Deisseroth, AB; Feldman, E; Hester, J; Kantarjian, HM; Korbling, M; Liang, J; Rios, MB; Smith, TL; Talpaz, M	1
Canellos, GP; Griffin, JD; Matulonis, UA	1
Kantarjian, HM; Talpaz, M	2
Du, M; Gandhi, V; Kantarjian, HM; Plunkett, W	1
Choudhury, S; Hait, WN; Murren, JR; Srimatkandada, S	1
Ambrosetti, A; Aprili, F; Krampera, M; Martinelli, G; Meneghini, V; Perona, G; Pizzolo, G; Veneri, D	1
Bauduer, F; Blanc, MC; Cadiou, M; Delmas-Marsalet, B; Delmer, A; Marie, JP; Rio, B; Zittoun, R	1
Björkholm, M; Gruber, A; Liliemark, EK; Liliemark, J; Peterson, C; Pettersson, B	1
Alimena, G; Bernasconi, P; Caricchi, P; Donti, E; Lazzarino, M; Liberati, AM; Mancini, M; Merante, S; Montefusco, E; Morra, E	1
Abgrall, JF; Bauters, F; Brice, P; Cassasus, P; Dine, G; Guilhot, F; Harousseau, JL; Ifrah, N; Rochant, H; Tilly, H	1
Baker, M; Bhalla, K; Grant, S	1
Dénes, R; Földi, J; Jakab, K; Jánossa, M; Kelemen, E; Váradi, G	1
Canellos, GP; Cannistra, SA; Griffin, JD; Robertson, MJ; Tantravahi, R	1
Harbott, J; Lampert, F; Li, L; Lohmeyer, J; Pralle, H; Ritterbach, J; Schroyens, W	1
Abbrederis, C; Baldinger, C; Duba, C; Fluckinger, T; Huber, C; Huber, H; Lang, A; Seewann, H; Silly, H; Thaler, J	1
Thaler, J	1
Babacan, E; Bökesoy, I; Cavdar, AO; Gözdaşoğlu, S; Pamĭr, A; Sunguroğlu, A; Tanindi, S; Türker, A; Unal, E; Yavuz, G	1
Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P	1
Pratila, MG; Pratilas, V; Steinherz, LJ	1
Hashimoto, S; Shibata, A	1
Cortes-Franco, J; Estey, E; Kornblau, SM	1
Cohen, PR	1
Akerman, S; Allen, SL; Barile, B; Budman, DR; DeMarco, LC; Kreis, W; Marsh, JH; Schulman, P; Schuster, MW	1
Arthur, CK; Ma, DD	1
Amiel, A; Einat, M; Fabian, I; Kashman, Y; Lishner, M; Markel, D; Nagler, A; Rudi, A; Yarkorli, S	1
Helbig, W; Krahl, R; Schulze, E; Thalmeier, K	1
Heinemann, V; Jehn, U; Pötscher, C	1
Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tzeng, CH; Wei, CH; Yu, IT	1
Anderlini, P; Kantarjian, HM; O'Brien, S; Talpaz, M	1
Mark, HF; Medeiros, LJ; Miranda, RN; Rintels, P; Wu, CD	1
Herzig, RH	1
Nakamura, T; Ueda, T; Yamauchi, T	1
Baranov, AE; Fleischman, EW; Frenkel, MA; Gordeeva, AA; Konstantinova, LN; Kulagina, OE; Volkova, MA	1
da Silva, P; Pawelec, G; Rehbein, A; Schlotz, E	1
Cortes, JE; Kantarjian, H; Talpaz, M	1
Carella, AM; Frassoni, F	1
Amadori, S; Fazi, P; Mandelli, F; Montefusco, E; Petti, MC; Picardi, A; Testi, AM	1
Bartram, CR; Borkhardt, A; Harbott, J; Janka-Schaub, G; Janssen, JW; Kabisch, H; Lampert, F; Ludwig, WD; Ratei, R; Reinisch, I; Repp, R; Riehm, H; Ritterbach, J; Schlieben, S; Schrappe, M; Zimmermann, M	1
Balleisen, L; Diedrich, H; Fonatsch, C; Freund, M; Grote-Metke, A; Heussner, P; Hild, F; Hinrichs, HF; Kleine, HD; Koch, O; Link, H; Meran, J; Nowak, R; Otremba, B; Poliwoda, H; von Wussow, P	1
Amabile, M; Arpinati, M; Farabegoli, P; Martinelli, G; Testoni, N; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL; Zuffa, E	1
Hilbe, W; Thaler, J	1
Aulitzky, WE; Busemann, C; Huber, C; Huhn, D; Kolbe, K; Neubauer, A; Peschel, C; Schleiermacher, E; Schneller, F; Siegert, W	1
Amiel, A; Einat, M; Fabian, I; Fejgin, MD; Kashman, Y; Nagler, A; Rudi, A	1
Ahmed, T; Darzynkiewicz, Z; Feldman, EJ; Halicka, HD; Lake, D; Seiter, K; Traganos, F	1
Abbrederis, K; Apfelbeck, U; Bernhart, M; Duba, C; Fluckinger, T; Fridrik, M; Geissler, D; Greil, R; Grünewald, K; Hausmaninger, H; Hilbe, W; Konwalinka, G; Lang, A; Lin, W; Linkesch, W; Ludwig, H; Niederwieser, D; Niessner, H; Pont, J; Seewann, H; Sill, H; Stöger, M; Thaler, J	1
Arthur, C; Ma, DD; Nevell, DF; Straetmans, N	1
Alimena, G; Amadori, S; Avvisati, G; Capria, S; Celesti, F; Latagliata, R; Mandelli, F; Montefusco, E; Petti, MC	1
Baccarani, M; Damiani, D; Manfroi, S; Michelutti, A; Ottaviani, E; Russo, D; Tosi, P; Tura, S; Visani, G	1
Capria, S; Mandelli, F; Meloni, G; Modena, V; Vignetti, M	1
Hall, JL; Hamblin, TJ; Myint, H; Ross, FM	1
Abgrall, JF; Bouabdallah, R; Chastang, C; Cheron, N; Guerci, A; Guilhot, F; Guyotat, D; Harousseau, JL; Maloisel, F; Michallet, M; Nicolini, F; Tanzer, J	1
Goldman, JM	1
Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S	1
Beran, M; Estey, E; Kantarjian, HM; Keating, MJ; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Sacchi, S; Talpaz, M	1
Alpdoğan, O; Alpdoğan, TB; Bayik, M; Demirçay, Z; Gürbüz, O; Kurtkaya, O; Yücelten, D	1
Niewint, AW; Ossenkoppele, GJ; Schuurhuis, GJ; Theijsmeijer, AP; Thijsen, SF; van Oostveen, JW	1
Patel, T; Roychowdhury, DF	1
Asano, S; Kikuchi, A; Nishikawa, T; Okamoto, S; Takahashi, S	1
Amarante-Mendes, GP; Bhalla, K; Green, DR; Huang, Y; Liu, L; Naekyung Kim, C; Perkins, CL	1
Finney, R; Irving, JA; Lennard, A; Proctor, SJ	1
Asano, S; Inoue, T; Nagayama, H; Nishiwaki, K; Okamoto, S; Oshima, Y; Takahashi, S; Tani, K; Tojo, A	1
Cornelissen, JJ; Löwenberg, B	1
Audisio, E; Chiusa, L; Marmont, F; Pich, A	1
Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF	1
Bhatia, R; DeFor, T; Hirsch, B; McGlave, PB; Miller, JS; Steinbuch, M; Verfaillie, CM; Weisdorf, D	1
Bode, U; Fleischhack, G; Graf, N; Hasan, C; Mann, G	1
Buño, I; Dewald, GW; Dietz-Band, J; Silver, RT; Wyatt, WA; Zinsmeister, AR	1
Delmer, A; Marie, JP	1
Abbrederis, K; Apfelbeck, U; Arneitz, K; Baldinger, C; Bernhart, M; Duba, C; Eisterer, W; Fridrik, M; Gastl, G; Greil, R; Hausmaninger, H; Hilbe, W; Konwalinka, G; Linkesch, W; Michlmayr, G; Niederwieser, D; Niessner, H; Pont, J; Thaler, J	1
Hasenclever, D; Loeffler, M; Tsodikov, A	1
Baer, MR; Herzig, GP; Jenis, EH; Mookerjee, BK; Schriber, JR; Shah, M; Wetzler, M	1
Aulitzky, W; Huber, C; Peschel, C; Schneller, F; Schuler, M; Schumacher, K; Thaler, J	1
Hayashi, S; Inatomi, Y; Iwama, H; Katagiri, T; Kawakubo, K; Kuriyama, Y; Miyazawa, K; Nehashi, Y; Ohyashiki, K; Shimamoto, T; Shyohji, N; Toyama, K; Uchida, Y; Yaguchi, M	1
Bertone, A; Marin, L; Martinelli, G; Russo, D; Testoni, N; Tiribelli, M	1
Chiba, S; Hirai, H; Honda, H; Kanda, Y; Yazaki, Y	1
Guilhot, F	1
Andreeff, M; Beran, M; Cortes, J; Giles, FJ; Giralt, S; Kantarjian, HM; Keating, MJ; Koller, C; Kornblau, S; O'Brien, S; Rios, MB; Smith, TL; Talpaz, M	1
Dewald, GW; Silver, RT; Wyatt, WA	1
Hawrylecka, D; Sacha, T; Skotnicki, AB	1
Aulitzky, W; Döhner, H; Domkin, D; Fischer, T; Huber, C; Huhn, D; Koch, B; Kolb, HJ; Kreiter, H; Lindauer, M; Neubauer, A	1
Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB	1
Chang, J; Dexter, TM; Dürig, J; Heyworth, CM; Kasper, C; Lord, BI; Telford, N; Testa, NG	1
Cortes, J; Freireich, EJ; Gajewski, J; Giles, FJ; Kantarjian, HM; Koller, C; Kornblau, S; O'Brien, S; Rios, MB; Sacchi, S; Talpaz, M	1
Cortes, J; Kantarjian, H; O'Brien, S; Rios, MB; Rodriguez, J; Smith, TL; Talpaz, M	1
Menéndez, B; Salar, A; Sierra, J; Sureda, A	1
Hensley, ML; Larson, RA; Peterson, B; Schiffer, CA; Silver, RT; Szatrowski, TP	1
Avalos, M; Barta, A; Bátai, A; Fekete, E; Földi, J; Gyódi, E; Hoffer, I; Jakab, J; Kelemen, E; Lengyel, L; Páldi-Haris, P; Pálóczi, K; Petrányi, GG; Rajczy, K; Reményi, P; Sipos, A; Tamáska, J; Torbágyi, E	1
Amabile, M; Baccarani, M; Bonifazi, F; De Vivo, A; Farabegoli, P; Martinelli, G; Montefusco, V; Ottaviani, E; Rosti, G; Russo, D; Saglio, G; Terragna, C; Testoni, N; Tura, S	1
Ohnishi, K	2
Cornelissen, JJ; Hagemeijer, A; Janssen, JJ; Nieuwint, AW; Ossenkoppele, GJ; Schuurhuis, GJ; Släter, R; van den Berg, E; van der Holt, B; van Rijn, RS; Vellenga, E; Verhoef, GE	1
Korycka, A; Lech-Maranda, E; Robak, T	1
Ezaki, K	1
Davidson, RJ; Goldman, JM; Gordon, MY; Marley, SB	2
Fricová, M; Guman, T; Hlebasková, M; Kafková, A; Raffac, S; Stecová, N; Tóthová, E	1
Copia, C; Ferrara, F; Leoni, P; Mele, G; Montillo, M; Morra, E; Nosari, A; Tedeschi, A	1
Fricová, M; Guman, T; Hlebasková, M; Kafková, A; Mudronová, B; Raffac, S; Stecová, N; Svorcová, E; Tóthová, E	1
Consoli, U; Giustolisi, GM; Giustolisi, R; Guglielmo, P; Inghilterra, G; Palumbo, GA; Stagno, F	1
Chen, X; Greinix, HT; Haas, OA; Kalhs, P; Keil, F; Lechner, K; Loidolt, H; Louda, N; Mannhalter, C; Mitterbauer, G; Moser, K; Pirc-Danoewinata, H; Rabitsch, W; Worel, N	1
Fujii, N; Harada, M; Hiramatsu, Y; Ikeda, K; Imai, T; Ishimaru, F; Kozuka, T; Maeda, Y; Niiya, K; Shinagawa, K; Sunami, K; Takenaka, K	1
Fruehauf, S; Topaly, J; Zeller, WJ	1
Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S	1
Brunstein, CG; Mcglave, PB	1
Abdulkadyrov, KM; Kornilova, TA; Martynkevich, IS; Rukavitsyn, OA; Udal'eva, VI	1
Aoki, N; Beck, JR; Giles, FJ; Guilhot, F; Guilhot, J; Wirt, DP	1
Baer, MR; Barone, S; Block, AW; Lawrence, D; Sait, SN; Wetzler, M	1
Beran, M; Cortes, J; Giles, FJ; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Rios, MB; Talpaz, M	1
Fischer, T; Lindauer, M	1
Dachselt, K; Deininger, M; Doepper, J; Dölken, G; Edel, E; Fiedler, F; Franke, A; Freund, M; Helbig, W; Herold, M; Hoffmann, FA; Kettner, E; Krahl, R; Lange, T; Leiblein, S; Niederwieser, D; Pasold, R; Pönisch, W; Richter, P; Schultze, W; Schwalbe, E; Schwarzer, A; Steglich, J; Subert, R; Uhle, R; von Grünhagen, U; Winkelmann, C	1
Berger, U; Hehlmann, R; Hochhaus, A; Kuhn, C; Reiter, A	1
Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A	1
Banyai, A; Barta, A; Foldi, J; Gidali, J; Gopcsa, L; Kalasz, L; Pajor, L; Paloczi, K; Regeczy, N	1
Bornhäuser, M; Ehninger, G; Hertenstein, B; Kiehl, M; Kröger, N; Martin, H; Runde, V; Sayer, HG; Schetelig, J; Schwerdtfeger, R; Siegert, W; Theuser, C	1
Tojo, A	1
Ait Arkoub, Z; Arnulf, B; Chebbi, F; Fillet, AM; Lefrere, F; Varet, B	1
Arellano-Rodrigo, E; Carreras, E; Cervantes, F; Espinet, B; Hernández-Boluda, JC; Lloveras, E; Marín, P; Montserrat, E; Ocejo, A; Rovira, M; Solé, F	1
Dan, K; Inami, M; Inokuchi, K; Miyata, J; Tajika, K; Watanabe, A; Yamaguchi, H; Yokomizo, E	1
Amabile, M; Baccarani, M; Bonifazi, F; de Vivo, A; Fiacchini, M; Martinelli, G; Montefusco, E; Rosti, G; Russo, D; Saglio, G; Testoni, N; Tura, S	1
Boccara, JF; Brice, P; Demeoq, F; Guilhot, F; Guilhot, J; Guyotat, D; Millot, F; Philippe, N; Thyss, A; Vilque, JP; Wetterwald, M	1
Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Resta, D; Rios, MB; Shan, J; Talpaz, M; Thomas, DA	1
Joel, SP; Liu, WM; Stimson, LA	1
Apperley, J; Clark, R; Goldman, J; Green, T; Holyoake, T; O'Brien, S; Shepherd, P	1
Asano, S; Ikeda, Y; Ishida, A; Izeki, T; Mori, T; Nagayama, H; Okamoto, S; Takahashi, S; Takayama, N; Tojo, A; Watanabe, R; Yokoyama, K	1
Jastrzebska, M; Lukowska, K; Pacholska, J; Paciorkiewicz, W; Rokicka-Milewska, R	1
Conrad, ME	1
Arakawa, M; Chou, T; Hayashi, N; Wakabayashi, M	1
Abakumov, EM; Isaev, VG; Khoroshko, ND; Navashin, SM; Savchenko, VG; Sokolov, AN; Turkina, AG; Viadro, MM	1
Brunner, K; Dear, KB; Haurani, F; Holland, JF; Karanas, A; Silver, RT; Weil, M	1
Christodoulidou, F; Macera, MJ; Silver, RT; Verma, RS	1
Beran, M; Estey, EH; Feldman, E; Kantarjian, HM; Keating, MJ; Koller, C; O'Brien, S; Pierce, S; Talpaz, M	1
Hempling, RE; Piver, MS; Sprance, HE	1
Akerman, S; Arlin, Z; Baskind, P; Budman, DR; DeAngelis, L; Feldman, EJ; Kreis, W; Lesser, M	1
Banavali, SD; Bokari, SA; Finke, D; Gopal, V; Preisler, HD	1
Beran, M; Deisseroth, A; Estey, EH; Gutterman, J; Kantarjian, HM; Keating, MJ; Kontoyiannis, D; O'Brien, S; Rios, MB; Talpaz, M	1
Bauters, F; Casassus, P; Dine, G; Guilhot, F; Harousseau, JL; Ifrah, N; Lamagnère, JP; Rochant, H; Tanzer, J; Tilly, H	1
Bhandal, AK; Carter, DL; Moore, DC; Studzinski, GP	1
Beran, M; Estey, EH; Freireich, EJ; Gutterman, J; Kantarjian, HM; Keating, MJ; McCredie, KB; O'Brien, S; Talpaz, M	1
Gutterman, JU; Kantarjian, H; Kurzrock, R; Talpaz, M	1
Brodsky, I; Bulova, S; Conroy, J; Crilley, P; Gryn, J; Kahn, SB; Topolsky, D; Weiss, J	1
Miura, Y; Sasaki, R; Takaku, F; Yoshida, H	1
Kim, SH; Kondo, T; Nishimura, T; Okabe, T; Okazaki, K; Suzuki, H; Tanaka, N	1
Gonzales-Chambers, R; Przepiorka, D	1
Borrego, D; Molina, R	1
Ahmad, M; Brizard, A; Dreyfus, B; Guilhot, F; Huret, JL; Kitzis, A; Mahon, FX; Tanzer, J	1
Kharbanda, SM; Kufe, DW; Sherman, ML	1
Büchner, T; Hiddemann, W; Krehmeier, C; Zühlsdorf, M	1
Gattringer, C; Konwalinka, G; Linkesch, W; Thaler, J	1
Carcassonne, Y; Gastaut, JA; Launay, MC; Lejeune, C; Maraninchi, D; Richard, B; Sainty, D; Sebahoun, G; Tubiana, N	1
Festa, RS; Lanzkowsky, P; Shende, A	1
Barone, JE; Barone, JG; DiGiacomo, JC; Snyder, AB	1
Bender-Götze, C; Haas, RJ; Holler, E; Kolb, HJ; Thierfelder, S; Wilmanns, W	1
Ahmed, T; Arlin, ZA; Feldman, EJ; Liebowitz, D; Shapiro, LR; Wilmot, PL	1
Busch, F; Pawelec, G; Rehbein, A; Schmidt, H	1
Canellos, GP	1
Cannistra, SA; Griffin, JD; Groshek, P	1
Anger, B; Heimpel, H	1
Maruyama, Y; Nagata, K; Nakamura, S; Onozawa, Y; Sakamaki, H; Yahara, Y	1
Andreeff, M; Berman, E; Clarkson, BD; Gabrilove, J; Gee, TS; Gulati, S; Kempin, SJ; Raymond, V; Wiernik, PH; Young, CW	1
David, JC; Maniey, D; Marquet, J; Zittoun, J; Zittoun, R	1
Brizard, A; Desmarest, MC; Dreyfus, B; Giraud, C; Guilhot, F; Huret, JL; Tanzer, J	1
Andreeff, M; Berman, E; Gabrilove, J; Gee, T; Gulati, S; Heller, G; Kempin, SJ; Kolitz, J; Raymond, V; Young, CW	1
Busch, FW; Pawelec, G	1
Cavelli, F; Degnan, TJ; Holland, JF; Mick, R; Silver, RT	1
Hatae, Y; Hatayama, Y; Nakadate, H; Takeda, T	1
Canellos, GP; Ernst, TJ; Griffin, JD; Rosenthal, DS	1
Crawford, SW; Johnson, NT; Sargur, M	1

Reviews

47 review(s) available for cytarabine and Granulocytic Leukemia, Chronic

Article	Year
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). International journal of hematology, 2020, Volume: 112, Issue:3 Topics: Cytarabine; Dasatinib; Drug Monitoring; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines	2020
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. Blood cancer journal, 2020, 11-23, Volume: 10, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Decitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides	2020
Therapy for Chronic Myelomonocytic Leukemia in a New Era. Current hematologic malignancy reports, 2017, Volume: 12, Issue:5 Topics: Allografts; Cytarabine; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Stem Cell Transplantation; World Health Organization	2017
Pseudozyma and other non-Candida opportunistic yeast bloodstream infections in a large stem cell transplant center. Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:2 Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cryptococcus; Cytarabine; Dermatomycoses; Echinocandins; Exanthema; Fever; Fungemia; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopeptides; Male; Micafungin; Opportunistic Infections; Retrospective Studies; Saccharomyces; Salvage Therapy; Trichosporon; Ustilaginales; Vidarabine; Voriconazole; Yeasts	2017
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML). European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic	2009
[History, current status, and future prospects in clinical study of myeloid leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10 Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Design; Drug Therapy, Combination; Gene Targeting; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Precision Medicine; Pyrimidines; Remission Induction; Risk; Tretinoin	2009
Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. Current hematologic malignancy reports, 2006, Volume: 1, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Multicenter Studies as Topic; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Rate; Vincristine	2006
Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer science, 2010, Volume: 101, Issue:7 Topics: Animals; Arsenic Trioxide; Arsenicals; beta Catenin; Bone Marrow; Cell Cycle; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Oxides; Protein Kinase Inhibitors; Protein-Tyrosine Kinases	2010
[Interferon-alpha in treatment of patients with chronic myeloid leukemia--indications and results]. Polskie Archiwum Medycyny Wewnetrznej, 2001, Volume: 105 Suppl Topics: Combined Modality Therapy; Cytarabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Treatment Outcome	2001
[Chronic myeloid leukemia--treatment]. Deutsche medizinische Wochenschrift (1946), 2002, Dec-06, Volume: 127, Issue:49 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Risk Factors; Stem Cell Transplantation	2002
[How I treat...chronic myeloid leukemia]. Revue medicale de Liege, 2003, Volume: 58, Issue:1 Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2003
Purine nucleoside analogues in the treatment of myleoid leukemias. Leukemia & lymphoma, 2003, Volume: 44, Issue:3 Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine	2003
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials. Seminars in hematology, 2003, Volume: 40, Issue:2 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Protocols; Clinical Trials as Topic; Cytarabine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines	2003
Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Examination; Clinical Trials as Topic; Cytarabine; Diagnosis, Differential; Drug Resistance; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Prognosis; Pyrimidines; Risk Factors; Sirolimus; Stem Cell Transplantation; Time Factors	2003
[Recent progress in diagnosis of and therapy for patients with leukemia]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Mar-10, Volume: 93, Issue:3 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Monitoring; Fusion Proteins, bcr-abl; Gene Targeting; Genes, Wilms Tumor; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Pharmacogenetics; Piperazines; Pyrimidines; Recombinant Fusion Proteins; Therapeutic Equivalency; Tretinoin	2004
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia. European journal of haematology, 2004, Volume: 72, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Burkitt Lymphoma; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Remission Induction	2004
Imatinib mesylate in the treatment of chronic myelogenous leukemia. International journal of hematology, 2004, Volume: 79, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Recurrence; Stem Cell Transplantation	2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia. Leukemia, 2004, Volume: 18, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Chromosome Aberrations; Controlled Clinical Trials as Topic; Cytarabine; Cytogenetic Analysis; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Primary Myelofibrosis; Prospective Studies; Risk Factors; Survival Rate	2004
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clinic proceedings, 2005, Volume: 80, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Treatment Outcome	2005
[Tyrosine kinase inhibitors for the treatment of CML]. Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase II as Topic; Cytarabine; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Time Factors	2006
[Chronic myelogenous leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:7 Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Therapy, Combination; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2006
Adult leukaemia in 1995: new directions. Lancet (London, England), 1995, Aug-19, Volume: 346, Issue:8973 Topics: Adult; Aged; Bone Marrow Transplantation; Child; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Translocation, Genetic; Tretinoin	1995
Mobilisation of Ph-negative peripheral blood stem cells in CML with idarubicin and cytarabine. Bone marrow transplantation, 1994, Volume: 14 Suppl 3 Topics: Cell Separation; Cytarabine; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Transplantation, Autologous	1994
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia. Seminars in oncology, 1994, Volume: 21, Issue:6 Suppl 14 Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Transplantation, Autologous; Transplantation, Homologous	1994
Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. Leukemia & lymphoma, 1993, Volume: 10, Issue:3 Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Life Tables; Male; Middle Aged; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome	1993
[Value of interferon-alpha in treatment of chronic myeloid leukemia]. Acta medica Austriaca, 1993, Volume: 20, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Cytarabine; Humans; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Survival Rate	1993
[Interferon therapy for chronic myelogenous leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Hydroxyurea; Immunity, Cellular; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; T-Lymphocytes; Vincristine	1993
Treatment of myelogenous leukemia: current status and investigational options. Blood, 1996, Apr-15, Volume: 87, Issue:8 Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cytarabine; Harringtonines; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Treatment Outcome	1996
Chronic myelogenous leukemia: a review. The American journal of medicine, 1996, Volume: 100, Issue:5 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cytarabine; Drug Therapy, Combination; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Prognosis; Time Factors	1996
[Recent progress in therapy for chronic myelogenous leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:9 Topics: Age Factors; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate	1997
[Developments in the treatment of patients with chronic myeloid leukemia]. Nederlands tijdschrift voor geneeskunde, 1997, Oct-04, Volume: 141, Issue:40 Topics: Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Humans; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Middle Aged	1997
[Update on malignant hematologic diseases]. Bulletin du cancer, 1998, Volume: 85, Issue:1 Topics: Antineoplastic Agents; Cytarabine; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Multiple Myeloma	1998
Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer, 1998, Nov-01, Volume: 83, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Glomerulosclerosis, Focal Segmental; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Proteinuria	1998
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate. Leukemia & lymphoma, 1999, Volume: 33, Issue:1-2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Etoposide; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Methotrexate; Mitoxantrone; Remission Induction; Time; Treatment Outcome	1999
[Autologous hemopoietic stem cell transplantation in treatment of chronic myelogenous leukemia]. Przeglad lekarski, 1999, Volume: 56 Suppl 1 Topics: Algorithms; Cytarabine; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Tissue Donors	1999
Immunological importance of chimerism in transplantation: new conditioning protocol in BMT and the development of chimeric state. Human immunology, 2000, Volume: 61, Issue:2 Topics: Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitobronitol; Transplantation Chimera; Treatment Outcome	2000
[Interferon-alpha therapy in chronic myelogenous leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:4 Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cytarabine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive	2000
Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Randomized Controlled Trials as Topic; Survival Analysis	2000
The biology and treatment of chronic myelogenous leukemia. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Benzamides; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Survival Analysis	2001
Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits. Leukemia & lymphoma, 2001, Volume: 41, Issue:5-6 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive	2001
[Chronic myelogenous leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Survival Rate	2001
AraC-based pharmacotherapy of chronic myeloid leukaemia. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:7 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleotides; Clinical Trials as Topic; Cytarabine; Cytidine Monophosphate; Drug Administration Schedule; Guidelines as Topic; Humans; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Survival Analysis	2001
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia. Bone marrow transplantation, 2001, Volume: 28, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation	2001
[Interferon-alpha therapy]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:12 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive	2001
Philadelphia chromosome-positive acute myeloid leukemia with tetraploidy. International journal of hematology, 2002, Volume: 75, Issue:1 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Polyploidy; Prednisolone; Remission Induction; RNA, Messenger; RNA, Neoplasm	2002
Treatment of chronic granulocytic leukemia in blastic crisis. Bone marrow transplantation, 1989, Volume: 4 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Transfusion; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Splenectomy	1989
[Chronic myelocytic leukemia following chemotherapy of acute promyelocytic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1989, Volume: 30, Issue:11 Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Remission Induction	1989

Trials

83 trial(s) available for cytarabine and Granulocytic Leukemia, Chronic

Article	Year
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia, 2021, Volume: 35, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Survival Rate; Young Adult	2021
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-10, Volume: 32, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk Factors; Time Factors; Treatment Outcome; Young Adult	2014
Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies. Leukemia research, 2015, Volume: 39, Issue:6 Topics: Adolescent; Adult; Allografts; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Family; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Whole-Body Irradiation	2015
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood, 2015, Jul-02, Volume: 126, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Comorbidity; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult	2015
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:1 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate	2016
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. The New England journal of medicine, 2017, 03-09, Volume: 376, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Intention to Treat Analysis; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Young Adult	2017
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Staging; Palliative Care; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Time Factors; Treatment Outcome	2009
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica, 2009, Volume: 94, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Over Studies; Cytarabine; Diarrhea; Drug Administration Schedule; Edema; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Muscle Cramp; Nausea; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome	2009
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010, Mar-11, Volume: 115, Issue:10 Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Transplantation Conditioning; Transplantation, Homologous	2010
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica, 2010, Volume: 95, Issue:6 Topics: Adult; Aged; Benzamides; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult	2010
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leukemia research, 2011, Volume: 35, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Exanthema; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Prospective Studies; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult	2011
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia, 2012, Volume: 26, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Remission Induction; Survival Rate; Young Adult	2012
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult	2012
Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study. British journal of haematology, 2013, Volume: 161, Issue:2 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies	2013
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group. British journal of haematology, 2002, Volume: 118, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate	2002
Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone. Haematologia, 2002, Volume: 32, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome	2002
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome	2003
A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. Leukemia, 2003, Volume: 17, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Prodrugs; Recombinant Proteins; Remission Induction; Treatment Outcome	2003
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leukemia & lymphoma, 2003, Volume: 44, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Central Nervous System Diseases; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recombinant Proteins; Survival Analysis	2003
Quality of life on imatinib. Seminars in hematology, 2003, Volume: 40, Issue:2 Suppl 2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cross-Over Studies; Cytarabine; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Quality of Life; Treatment Outcome	2003
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Seminars in hematology, 2003, Volume: 40, Issue:2 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome	2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer, 2003, Jun-15, Volume: 97, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cytarabine; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome	2003
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood, 2003, Dec-15, Volume: 102, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Safety; Thrombocytopenia	2003
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer, 2003, Sep-01, Volume: 98, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Drug Administration Schedule; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome	2003
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 2003, Volume: 17, Issue:12 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Bone Marrow; Cross-Over Studies; Cytarabine; Cytogenetics; DNA Mutational Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotransferases; Piperazines; Prognosis; Protein Structure, Tertiary; Pyrimidines; Treatment Outcome	2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia, 2003, Volume: 17, Issue:12 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cross-Over Studies; Cytarabine; Cytogenetics; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Risk Factors; RNA, Messenger; Treatment Outcome	2003
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. The New England journal of medicine, 2003, Oct-09, Volume: 349, Issue:15 Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic	2003
[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study]. Der Internist, 2004, Volume: 45, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome	2004
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Annals of hematology, 2004, Volume: 83, Issue:11 Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine	2004
[The 6M 12M trial--study of the effectivess and tolerance of treatment in chronic myeloid leukaemia with a combination of interferon alfa and cytarabine]. Vnitrni lekarstvi, 2000, Volume: 46, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recombinant Proteins; Remission Induction	2000
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Carriers; Drug Combinations; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Maximum Tolerated Dose; Middle Aged; Polyethylene Glycols; Recombinant Proteins	2005
Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia. Pediatric blood & cancer, 2006, Oct-15, Volume: 47, Issue:5 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prospective Studies; Recombinant Proteins; Survival Rate; Treatment Outcome	2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England journal of medicine, 2006, Dec-07, Volume: 355, Issue:23 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Survival Rate; Treatment Outcome	2006
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer, 2007, Apr-15, Volume: 109, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Etoposide; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome	2007
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood, 2008, Mar-01, Volume: 111, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Communicable Diseases; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hematologic Tests; Humans; Imatinib Mesylate; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mortality; Piperazines; Pyrimidines	2008
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Monitoring; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Methemoglobinemia; Middle Aged; Pyridines; Recurrence; Thiosemicarbazones	2008
Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis. Leukemia, 1994, Volume: 8, Issue:1 Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; HLA-DR Antigens; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged	1994
Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia. Journal of hematotherapy, 1994,Fall, Volume: 3, Issue:3 Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; HLA-DR Antigens; Humans; Idarubicin; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Treatment Outcome	1994
Rapid control of chronic granulocytic leukaemia. African journal of medicine and medical sciences, 1993, Volume: 22, Issue:2 Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Female; Hepatomegaly; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Remission Induction; Splenomegaly; Time Factors	1993
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. American journal of hematology, 1994, Volume: 45, Issue:4 Topics: Adult; Blood Transfusion, Autologous; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Transplantation, Autologous	1994
Evolving approaches with interferon alfa in chronic myelogenous leukemia. Seminars in hematology, 1993, Volume: 30, Issue:3 Suppl 3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recombinant Proteins; Treatment Outcome	1993
Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center. Leukemia & lymphoma, 1993, Volume: 11 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Drug Therapy, Combination; Follow-Up Studies; Humans; Hydroxyurea; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Tables; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Texas; Treatment Outcome; Vincristine	1993
A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results. Leukemia & lymphoma, 1993, Volume: 11 Suppl 1 Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Cytarabine; Female; France; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Recombinant Proteins; Remission Induction; Treatment Outcome	1993
Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report. Leukemia, 1993, Volume: 7, Issue:12 Topics: Adult; Aged; Blast Crisis; Cytarabine; Deoxycytidine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia	1993
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Chemical and Drug Induced Liver Injury; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma	1993
Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta haematologica, 1993, Volume: 89 Suppl 1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metaphase; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins	1993
Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach. Leukemia & lymphoma, 1995, Volume: 19, Issue:1-2 Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged	1995
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia. Leukemia, 1996, Volume: 10, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome	1996
Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia, 1996, Volume: 10, Issue:6 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Base Sequence; Child; Child, Preschool; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Germany; Humans; Incidence; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Methotrexate; Molecular Sequence Data; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Prospective Studies; Transcription, Genetic; Translocation, Genetic; Vincristine	1996
Comparative analysis of two consecutive phase II studies with IFN-alpha and IFN-alpha + ara-C in untreated chronic-phase CML patients. Austrian CML Study Group. Bone marrow transplantation, 1996, Volume: 17 Suppl 3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Austria; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Recombinant Proteins; Retrospective Studies	1996
Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3. Bone marrow transplantation, 1996, Volume: 17 Suppl 3 Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Interleukin-3; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Philadelphia Chromosome	1996
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study. Leukemia research, 1997, Volume: 21, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Prospective Studies; Recombinant Proteins; Remission Induction	1997
Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction	1997
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. The New England journal of medicine, 1997, Jul-24, Volume: 337, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recombinant Proteins; Regression Analysis; Survival Analysis	1997
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:8 Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine	1997
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia, 1997, Volume: 11, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxyurea; Interferon Type I; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prognosis; Recombinant Proteins; Time Factors	1997
Molecular remission in Philadelphia-positive adult acute lymphoblastic leukaemia rapidly induced by conventional-dose chemotherapy. Bone marrow transplantation, 1998, Volume: 21, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mitoxantrone; Pilot Projects; Polymerase Chain Reaction; Remission Induction; Vidarabine	1998
Nucleolar organizer region counts predict complete remission, remission duration, and survival in adult acute myelogenous leukemia patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4 Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cell Division; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nucleolus Organizer Region; Predictive Value of Tests; Prognosis; Remission Induction; Survival Rate	1998
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. British journal of haematology, 1998, Volume: 102, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Vidarabine	1998
A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood, 1998, Oct-01, Volume: 92, Issue:7 Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Cells; Bone Marrow; Cell Nucleus; Combined Modality Therapy; Cytarabine; DNA, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organ Specificity; Recombinant Proteins; Remission Induction; Treatment Outcome	1998
Regression with bounded outcome score: evaluation of power by bootstrap and simulation in a chronic myelogenous leukaemia clinical trial. Statistics in medicine, 1998, Sep-15, Volume: 17, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Humans; Hydroxyurea; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Statistical; Odds Ratio; Outcome and Process Assessment, Health Care; Regression Analysis; Remission Induction	1998
Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial. Annals of hematology, 1998, Volume: 77, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Survival Rate	1998
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Genetic Markers; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Prognosis; Risk Factors; Survival Rate	1999
Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia. British journal of haematology, 1999, Volume: 106, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pain; Recombinant Proteins; Survival Analysis; Treatment Outcome	1999
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer, 1999, Dec-01, Volume: 86, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Treatment Outcome; Vidarabine	1999
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leukemia & lymphoma, 1999, Volume: 35, Issue:5-6 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Female; Femur Head Necrosis; Humans; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Life Tables; Male; Middle Aged; Paranoid Disorders; Pilot Projects; Pseudotumor Cerebri; Pulmonary Edema; Red-Cell Aplasia, Pure; Remission Induction; Survival Analysis; Syncope; Treatment Outcome; Tretinoin	1999
Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests. Bone marrow transplantation, 2000, Volume: 25, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Transplantation, Autologous	2000
Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia. Neoplasma, 2000, Volume: 47, Issue:2 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Remission Induction	2000
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia, 2001, Volume: 15, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2001
High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. American journal of hematology, 2001, Volume: 67, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome	2001
Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leukemia & lymphoma, 2001, Volume: 41, Issue:3-4 Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prednisolone; Prednisone; Risk Factors; Survival Rate; Therapeutic Equivalency; Treatment Outcome; Vincristine	2001
Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens. Bone marrow transplantation, 2001, Volume: 27, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome	2001
A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood, 2002, Mar-01, Volume: 99, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetic Analysis; Female; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome	2002
Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Metaphase; Spleen; Treatment Outcome	2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood, 2002, May-15, Volume: 99, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Cytarabine; Cytogenetic Analysis; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome	2002
Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase. International journal of hematology, 2002, Volume: 75, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Transplantation, Isogeneic; Treatment Outcome; Whole-Body Irradiation	2002
[Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1992, Volume: 37, Issue:7 Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction	1992
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study. Leukemia & lymphoma, 1992, Volume: 7, Issue:1-2 Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lomustine; Male; Middle Aged; Remission Induction; Time Factors	1992
A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results. European journal of cancer (Oxford, England : 1990), 1991, Volume: 27 Suppl 4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hydroxyurea; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recombinant Proteins	1991
Bone marrow transplantation for the treatment of leukaemia-results of the Munich Cooperative Group. Folia haematologica (Leipzig, Germany : 1928), 1989, Volume: 116, Issue:3-4 Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Female; Germany, West; Graft vs Host Disease; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Survival Rate; Whole-Body Irradiation	1989
Idarubicin in acute leukemia: results of US trials. Bone marrow transplantation, 1989, Volume: 4 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute	1989
Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Daunorubicin; Female; Humans; Idarubicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction	1989
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis-chloronitrosurea during the course of busulfan-maintained remission. Cancer investigation, 1988, Volume: 6, Issue:3 Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lomustine; Male; Middle Aged; Random Allocation; Sex Factors	1988

Other Studies

178 other study(ies) available for cytarabine and Granulocytic Leukemia, Chronic

Article	Year
Zhongguo shi yan xue ye xue za zhi, 2023, Volume: 31, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Forkhead Transcription Factors; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; RNA, Messenger; T-Lymphocytes, Regulatory; Transforming Growth Factor beta	2023
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report. Current medical research and opinion, 2020, Volume: 36, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pyrimidines; Remission Induction; Transplantation, Autologous	2020
Eccrine squamous syringometaplasia in an allogenic stem cell transplant patient undergoing chemotherapy. Dermatology online journal, 2017, Sep-15, Volume: 23, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Eruptions; Eccrine Glands; Epithelial Cells; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metaplasia; Stem Cell Transplantation; Transplantation, Homologous	2017
An atypical isolated CNS blast crisis in chronic myeloid leukaemia. British journal of hospital medicine (London, England : 2005), 2018, Aug-02, Volume: 79, Issue:8 Topics: Aged; Antineoplastic Agents; Blast Crisis; Brain; Central Nervous System Diseases; Cytarabine; Glucocorticoids; Humans; Image Enhancement; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Maintenance Chemotherapy; Male; Methotrexate; Neuroimaging; Spinal Cord; Treatment Outcome	2018
Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder. Pediatric transplantation, 2018, Volume: 22, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Child; Cytarabine; Epstein-Barr Virus Infections; Female; Fusion Proteins, bcr-abl; Humans; Immunosuppression Therapy; Injections, Spinal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, B-Cell; Lymphoproliferative Disorders; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography Computed Tomography; Postoperative Period; Remission Induction; Rituximab; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome	2018
Primary Philadelphia chromosome positive acute myeloid leukemia: A case report. Medicine, 2018, Volume: 97, Issue:44 Topics: Antineoplastic Agents; Bone Marrow Examination; Cytarabine; Dasatinib; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Idarubicin; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multiple Organ Failure; Mutation; Philadelphia Chromosome	2018
Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia. Acta haematologica, 2019, Volume: 142, Issue:3 Topics: Adolescent; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Etoposide; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylprednisolone; Prednisolone; Pyridazines	2019
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer, 2014, Feb-01, Volume: 120, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Vincristine	2014
Primary distal femur T-cell lymphoma after allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia: a rare case report and literature review. The Journal of international medical research, 2014, Volume: 42, Issue:2 Topics: Adult; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Harringtonines; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell; Male; Neoplasm Invasiveness; Transplantation, Homologous	2014
Acute pleural and pericardial effusion induced by chemotherapy in treating chronic myelocytic leukemia. Clinical laboratory, 2014, Volume: 60, Issue:5 Topics: Adult; Antineoplastic Agents; Cytarabine; Daunorubicin; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pericardial Effusion; Pleural Effusion	2014
Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:7 Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Benzamides; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Imatinib Mesylate; Immunosuppressive Agents; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
[Dasatinib-related pneumonia? An example of pharmacovigilance survey]. Revue des maladies respiratoires, 2015, Volume: 32, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Pharmacovigilance; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Thiazoles; Tomography, X-Ray Computed; Vincristine	2015
Myelopathy following intrathecal chemotherapy in adults: a single institution experience. Journal of neuro-oncology, 2015, Volume: 122, Issue:2 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Myelin Basic Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Spinal Cord; Spinal Cord Diseases	2015
Successful administration of cytarabine in a 16-month-old girl with acute myelogenous leukemia and cytarabine syndrome. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2009, Volume: 102, Issue:2 Topics: Cytarabine; Diphenhydramine; Drug Hypersensitivity; Female; Histamine Antagonists; Humans; Immunosuppressive Agents; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Methylprednisolone; Premedication; Ranitidine; Syndrome; Treatment Outcome	2009
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leukemia & lymphoma, 2009, Volume: 50, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dasatinib; Dexamethasone; Female; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Radiotherapy; Recurrence; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome	2009
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood, 2009, Sep-10, Volume: 114, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine	2009
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. American journal of hematology, 2009, Volume: 84, Issue:10 Topics: Antineoplastic Agents; Aphasia; Ataxia; Benzamides; Blast Crisis; Confusion; Cytarabine; Diagnosis, Differential; Hearing Loss; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Stem Cell Transplantation; Treatment Outcome	2009
A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use. Acta haematologica, 2010, Volume: 123, Issue:4 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colitis; Cytarabine; Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Diseases; Thiazoles	2010
Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line. Leukemia & lymphoma, 2010, Volume: 51, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Marrow Cells; Cell Adhesion; Cell Survival; Cells, Cultured; Coculture Techniques; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Integrin beta1; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Stromal Cells	2010
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. European journal of haematology, 2011, Volume: 86, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Cytarabine; DNA Damage; Drug Synergism; Gene Expression; Genes, abl; Humans; Hydroxyurea; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Piperazines; Pyrimidines; Tumor Stem Cell Assay	2011
[Chronic myeloid leukemia complicated with cerebellar hemorrhage and acute hydrocephalus successfully treated with imatinib and intensive supportive care]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:12 Topics: Acute Disease; Antineoplastic Agents; Benzamides; Cerebellum; Cerebral Hemorrhage; Combined Modality Therapy; Critical Care; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocephalus; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukostasis; Mannitol; Middle Aged; Piperazines; Pyrimidines; Respiration, Artificial	2010
Bilateral irreversible blindness in leukaemic meningitis: cause or cure? Annals of hematology, 2011, Volume: 90, Issue:12 Topics: Antimetabolites, Antineoplastic; Blindness; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Meningitis; Middle Aged; Optic Nerve; Retina	2011
Successful treatment of childhood Philadelphia chromosome-positive acute myeloid leukemia. Pediatrics international : official journal of the Japan Pediatric Society, 2011, Volume: 53, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Cytarabine; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Piperazines; Pyrimidines	2011
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica, 2012, Volume: 97, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dasatinib; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Thiazoles; Treatment Outcome; Vidarabine	2012
Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy. Leukemia research, 2012, Volume: 36, Issue:10 Topics: Benzamides; Cytarabine; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thymidine; Tumor Cells, Cultured	2012
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer, 2002, May-15, Volume: 94, Issue:10 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Harringtonines; Homoharringtonine; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay	2002
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. Blood, 2002, Oct-01, Volume: 100, Issue:7 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Patient Selection; Ploidies; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Survival Analysis; Time Factors; Treatment Outcome	2002
[Quantitative analysis of Sokal's risk index in relation to 2 therapy protocols: their respective impact on clinical remission of chronic myeloid leukemia]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2002, Volume: 22, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Female; Harringtonines; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome Assessment, Health Care; Treatment Outcome	2002
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer research, 2002, Oct-15, Volume: 62, Issue:20 Topics: Benzamides; Benzoquinones; Blast Crisis; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidines; Rifabutin; src-Family Kinases; STAT5 Transcription Factor; Trans-Activators	2002
Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer genetics and cytogenetics, 2002, Volume: 137, Issue:2 Topics: Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human; Cytarabine; Cytogenetic Analysis; Humans; In Situ Hybridization, Fluorescence; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Randomized Controlled Trials as Topic; Recombinant Proteins	2002
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood, 2003, Mar-01, Volume: 101, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Blood Cells; Bone Marrow Cells; Clone Cells; Cohort Studies; Cytarabine; Dosage Compensation, Genetic; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Idarubicin; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Androgen; Remission Induction	2003
[Chronic myeloid leukemia--case report]. Deutsche medizinische Wochenschrift (1946), 2002, Dec-06, Volume: 127, Issue:49 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Cytarabine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Piperazines; Prognosis; Pyrimidines; Remission Induction	2002
Bilateral optic nerve infiltration in central nervous system leukemia. American journal of ophthalmology, 2003, Volume: 135, Issue:1 Topics: Antimetabolites, Antineoplastic; Blindness; Cytarabine; Humans; Injections, Spinal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Magnetic Resonance Imaging; Male; Middle Aged; Optic Nerve; Visual Acuity	2003
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. European journal of haematology, 2003, Volume: 70, Issue:4 Topics: Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosome Aberrations; Chromosome Painting; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fatal Outcome; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous	2003
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias. Hematology (Amsterdam, Netherlands), 2003, Volume: 8, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hepatitis B; Humans; Imatinib Mesylate; Immunosuppressive Agents; Lamivudine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Remission Induction; Salvage Therapy; Vincristine	2003
In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia, 2003, Volume: 17, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Caspases; Cell Division; Cytarabine; DNA; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Phosphorylation; Piperazines; Poly(ADP-ribose) Polymerases; Precipitin Tests; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Tyrosine; U937 Cells	2003
[Chronic myeloid leukemia. What's in the future therapy in Black Africa?]. La Tunisie medicale, 2003, Volume: 81, Issue:3 Topics: Adult; Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Congo; Cytarabine; Female; Follow-Up Studies; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Recombinant Proteins; Retrospective Studies; Sex Factors; Socioeconomic Factors; Time Factors	2003
cDNA microarray analysis of altered gene expression in Ara-C-treated leukemia cells. Biochemical and biophysical research communications, 2003, Sep-19, Volume: 309, Issue:2 Topics: Amino Acid Sequence; Apoptosis; Cell Differentiation; Cytarabine; DNA Mutational Analysis; Dose-Response Relationship, Drug; Gene Expression; Gene Expression Regulation; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondrial Proteins; Molecular Chaperones; Molecular Sequence Data; Oligonucleotide Array Sequence Analysis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured	2003
Minimal residual disease in chronic myeloid leukemia. The New England journal of medicine, 2003, Oct-09, Volume: 349, Issue:15 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic	2003
Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia. European journal of haematology, 2004, Volume: 72, Issue:1 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vidarabine	2004
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. International journal of hematology, 2004, Volume: 79, Issue:1 Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Division; Cell Line, Tumor; Cytarabine; Daunorubicin; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxyurea; Imatinib Mesylate; Imidazoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Pyrimidines; Vincristine; Zoledronic Acid	2004
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leukemia & lymphoma, 2004, Volume: 45, Issue:2 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction	2004
Polyethylene glycol interferon-alpha2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia. Haematologica, 2004, Volume: 89, Issue:7 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins	2004
Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004, Dec-01, Volume: 101, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Cytarabine; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Treatment Outcome	2004
Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004, Dec-01, Volume: 101, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Cost-Benefit Analysis; Cytarabine; Health Care Costs; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Retrospective Studies; Survival Analysis	2004
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 2005, Volume: 19, Issue:7 Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin	2005
Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematological oncology, 2004, Volume: 22, Issue:4 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Meninges; Methotrexate; Neoplasm Invasiveness; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction	2004
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. JPMA. The Journal of the Pakistan Medical Association, 2005, Volume: 55, Issue:6 Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine	2005
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene, 2005, Nov-03, Volume: 24, Issue:48 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Autoantigens; Cell Cycle Proteins; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Genetic Variation; Humans; Hydroxyurea; Idarubicin; In Situ Hybridization, Fluorescence; Janus Kinase 2; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins, Fusion; Open Reading Frames; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Secondary Prevention; Sequence Analysis, RNA; Translocation, Genetic; Treatment Outcome	2005
CML clonal evolution with resistance to single agent imatinib therapy. Clinical and laboratory haematology, 2005, Volume: 27, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Transformation, Neoplastic; Clone Cells; Cytarabine; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Treatment Failure; Trisomy	2005
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica, 2005, Volume: 90 Suppl Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine	2005
Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib. Haematologica, 2005, Volume: 90 Suppl Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Imatinib Mesylate; Interferons; Lenograstim; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Transplantation, Autologous	2005
Gene expression profiles of two accelerations in a CML patient. Leukemia research, 2006, Volume: 30, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mitoxantrone; Multigene Family; Oligonucleotide Array Sequence Analysis; Vidarabine	2006
Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2005, Volume: 3, Issue:6 Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Cytogenetic Analysis; Disease Progression; Drug Interactions; Gene Fusion; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferons; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recombinant Fusion Proteins; Remission Induction; Secondary Prevention; Translocation, Genetic; Transplantation, Homologous	2005
Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance. British journal of haematology, 2006, Volume: 132, Issue:6 Topics: Actins; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Division; Cell Line, Tumor; Cloning, Molecular; Cytarabine; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipids; Models, Biological; Neoplastic Stem Cells; Protein-Tyrosine Kinases; Temperature	2006
Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology, 2006, Volume: 105, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Humans; Hyperplasia; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vasodilator Agents	2006
Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG). Annals of hematology, 2006, Volume: 85, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Methotrexate; Middle Aged; Philadelphia Chromosome; Poland; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Treatment Outcome	2006
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. International journal of oncology, 2006, Volume: 28, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Marrow; Cytarabine; DNA Primers; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic	2006
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood, 2006, Sep-01, Volume: 108, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Splenomegaly; Survival Analysis; Treatment Failure; Treatment Outcome	2006
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anti-cancer drugs, 2006, Volume: 17, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine	2006
[Modulating effect of antileukemia drugs on the cellular susceptibility in chronic myeloid leukemia to cytotoxic lymphocytes]. Voprosy onkologii, 2006, Volume: 52, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Humans; Hydroxyurea; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear	2006
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. Journal of neuro-oncology, 2007, Volume: 84, Issue:1 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Methotrexate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Myeloid; Treatment Outcome	2007
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leukemia & lymphoma, 2007, Volume: 48, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Survival Rate; Treatment Outcome	2007
Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia. Expert review of anticancer therapy, 2007, Volume: 7, Issue:3 Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Binding Sites; Cross-Over Studies; Cytarabine; Disease-Free Survival; Drug Design; Drug Resistance, Neoplasm; Drugs, Investigational; Europe; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Neoplasm Proteins; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; src Homology Domains; Transplantation, Homologous; Treatment Outcome	2007
Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica, 2007, Volume: 92, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Feeding; Cytarabine; Embryonic Development; Female; Humans; Imatinib Mesylate; Immunologic Factors; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Recurrence; Remission Induction	2007
[The standard treatments for patients with hematological malignancies in Japan]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Rituximab; Survival Rate; Vincristine	2007
Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Mathematical biosciences, 2007, Volume: 210, Issue:1 Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Cytarabine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mathematics; Models, Biological; Piperazines; Pyrimidines; T-Lymphocytes	2007
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. European journal of clinical investigation, 2007, Volume: 37, Issue:10 Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Central Nervous System Neoplasms; Cytarabine; Dasatinib; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liposomes; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome	2007
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta haematologica, 2007, Volume: 118, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bile Ducts; Blast Crisis; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cytarabine; Drug Eruptions; Hepatocytes; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2007
A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis. Leukemia research, 1995, Volume: 19, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged	1995
Inhibition of erythroid differentiation by stem cell factor in K562 cells expressing the c-kit gene. Experimental hematology, 1994, Volume: 22, Issue:1 Topics: Blotting, Northern; Cell Differentiation; Cell Transformation, Neoplastic; Cytarabine; DNA, Neoplasm; Erythroid Precursor Cells; Erythropoiesis; Flow Cytometry; Gene Expression Regulation, Neoplastic; Hematopoietic Cell Growth Factors; Hemin; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Precipitin Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogenes; Receptor Protein-Tyrosine Kinases; Receptors, Colony-Stimulating Factor; RNA, Messenger; Stem Cell Factor; Transfection; Tumor Cells, Cultured; Tyrosine	1994
FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report. British journal of haematology, 1994, Volume: 86, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Vidarabine	1994
Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. European journal of haematology, 1995, Volume: 55, Issue:3 Topics: Adult; Aged; Combined Modality Therapy; Cytarabine; Female; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction	1995
Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells. Leukemia research, 1993, Volume: 17, Issue:11 Topics: Antineoplastic Agents; Azacitidine; Blast Crisis; Cytarabine; Decitabine; DNA, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors; Tumor Cells, Cultured	1993
Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone marrow transplantation, 1993, Volume: 12, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Blood Transfusion, Autologous; Cell Separation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; RNA, Messenger; RNA, Neoplasm; Time Factors; Treatment Outcome	1993
Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anti-cancer drugs, 1995, Volume: 6, Issue:1 Topics: Alkaloids; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Cycle; Cytarabine; DNA Replication; DNA, Neoplasm; Drug Resistance, Multiple; Drug Synergism; Female; Humans; Leukemia L1210; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred DBA; Neoplasm Proteins; Ovarian Neoplasms; Protein Kinase C; Staurosporine; Tumor Cells, Cultured	1995
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Separation; Cytarabine; Daunorubicin; Diploidy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine	1995
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia, 1994, Volume: 8, Issue:9 Topics: Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cytarabine; Deoxycytosine Nucleotides; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured	1994
Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents. The Journal of clinical investigation, 1993, Volume: 91, Issue:5 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Southern; Cell Differentiation; Cyclosporine; Cytarabine; DNA; Drug Resistance; Flupenthixol; Gene Expression; Hemin; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; RNA, Messenger; Transfection; Tumor Cells, Cultured; Vinblastine	1993
Early lymphoid blastic crisis following major karyotypic conversion in a chronic myeloid leukemia patient treated with interferon-alpha. International journal of clinical & laboratory research, 1994, Volume: 24, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Child; Cytarabine; Daunorubicin; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Prednisone; Recombinant Proteins; Remission Induction; Vincristine	1994
In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding. Leukemia & lymphoma, 1993, Volume: 10, Issue:4-5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Proteins; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Protein Binding; Serum Albumin; Topoisomerase II Inhibitors	1993
Non-supralethal mitobronitol/cytarabine/cyclophosphamide conditioning without irradiation before bone marrow transplantation for accelerated chronic granulocytic leukemia: apparent absence of acute graft-versus-host disease. Leukemia, 1993, Volume: 7, Issue:7 Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mitobronitol; Oligospermia	1993
Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. American journal of hematology, 1993, Volume: 43, Issue:2 Topics: Adult; Aged; Bone Marrow; Cytarabine; Cytogenetics; Female; Humans; Infusion Pumps; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Remission Induction; Stem Cells	1993
Blastic phase chronic myeloid leukemia with a four-break rearrangement: t(11;9)(9;22)(q23;p22q34;q11). Cancer genetics and cytogenetics, 1993, Jul-15, Volume: 68, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blast Crisis; Chromosome Banding; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Daunorubicin; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Translocation, Genetic; Vincristine	1993
Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside. Leukemia research, 1993, Volume: 17, Issue:8 Topics: Adult; Aged; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Female; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins	1993
Orbito-ocular granulocytic sarcoma (OOGS) and acute myeloblastic leukemia (AML) with duplication of Philadelphia chromosome. Cancer genetics and cytogenetics, 1993, Volume: 69, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Eye Neoplasms; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Multigene Family; Neoplasms, Multiple Primary; Orbital Neoplasms; Philadelphia Chromosome; Thioguanine	1993
Sick sinus syndrome in a teenager treated with idarubicin. Journal of cardiothoracic and vascular anesthesia, 1993, Volume: 7, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arrhythmia, Sinus; Bradycardia; Cytarabine; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Sick Sinus Syndrome	1993
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia, 1993, Volume: 7, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine	1993
The use of gemfibrozil in a patient with chronic myelogenous leukemia to successfully manage retinoid-induced hypertriglyceridemia. The Clinical investigator, 1993, Volume: 71, Issue:1 Topics: Acne Vulgaris; Adult; Combined Modality Therapy; Cytarabine; Gemfibrozil; Humans; Hydroxyurea; Hypertriglyceridemia; Immunologic Factors; Incidence; Isotretinoin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male	1993
Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer chemotherapy and pharmacology, 1993, Volume: 31, Issue:6 Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Cytarabine; Drug Resistance; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Tetrahydrouridine; Treatment Outcome	1993
Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients. Experimental hematology, 1995, Volume: 23, Issue:14 Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents; Bone Marrow; Cell Division; Cell Survival; Child; Child, Preschool; Cytarabine; Female; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Phenanthrolines; Tumor Cells, Cultured	1995
Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells. Experimental hematology, 1995, Volume: 23, Issue:14 Topics: Base Sequence; Bone Marrow Transplantation; Cytarabine; Fusion Proteins, bcr-abl; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured	1995
Trisomy 21 in acute myeloid leukemia. Cancer genetics and cytogenetics, 1996, Volume: 86, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Down Syndrome; Humans; Hydroxyurea; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Acute; Male; Mitoxantrone	1996
Chronic myeloid leukemia manifested during megakaryoblastic crisis. Southern medical journal, 1996, Volume: 89, Issue:4 Topics: Adult; Antimetabolites, Antineoplastic; Blast Crisis; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Fatal Outcome; Humans; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male	1996
High-dose ara-C in older adults with acute leukemia. Leukemia, 1996, Volume: 10 Suppl 1 Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Controlled Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Multicenter Studies as Topic; Remission Induction	1996
A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo. Cancer research, 1996, Apr-15, Volume: 56, Issue:8 Topics: Alkaline Phosphatase; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cell Line; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Radioimmunoassay; Sensitivity and Specificity; Tumor Cells, Cultured	1996
Translocation (2;3)(p13;q26) in two cases of myeloid malignancies. Acute myeloblastic leukemia (M2) and blastic phase of chronic myeloid leukemia. Cancer genetics and cytogenetics, 1996, Volume: 87, Issue:2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Prednisolone; Prednisone; Translocation, Genetic; Vincristine	1996
Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer immunology, immunotherapy : CII, 1996, Volume: 42, Issue:3 Topics: Cells, Cultured; Cytarabine; Cytokines; Histocompatibility Antigens Class II; Humans; Immunity, Cellular; Interleukin-1; Interleukin-10; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocytes	1996
Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia. Leukemia, 1996, Volume: 10 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recurrence; Remission Induction; Transplantation, Autologous	1996
[Therapy of chronic myeloid leukemia with interferon-alpha. A decade of experiences]. Medizinische Klinik (Munich, Germany : 1983), 1996, Apr-12, Volume: 91 Suppl 3 Topics: Antineoplastic Agents; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Long-Term Care; Survival Rate	1996
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia. Leukemia & lymphoma, 1996, Volume: 22, Issue:1-2 Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine	1996
Synergistic effects of interleukin-11 with other growth factors on the expansion of hematopoietic progenitors from normal individuals and chronic myeloid leukemia patients resistant to treatment with cytosine arabinoside or eilatin. Leukemia research, 1996, Volume: 20, Issue:9 Topics: Animals; Antineoplastic Agents; CHO Cells; Cricetinae; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interleukin-11; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenanthrolines; Stem Cell Factor; Tumor Stem Cell Assay	1996
Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Camptothecin; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Topotecan	1997
Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy. Hematopathology and molecular hematology, 1996, Volume: 10, Issue:4 Topics: Adult; Antigens; Antigens, CD; Antigens, CD34; Bone Marrow Examination; Cytarabine; E-Selectin; Endothelium; Female; Fibrosis; HLA-DR Antigens; Humans; Immunohistochemistry; Integrin beta3; Interferon-alpha; Lectins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Plant Lectins; Platelet Endothelial Cell Adhesion Molecule-1; Platelet Membrane Glycoproteins; Primary Myelofibrosis; Reticulin; Retrospective Studies; Staining and Labeling; Stromal Cells; von Willebrand Factor	1996
Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia, 1997, Volume: 11, Issue:5 Topics: Adult; Antineoplastic Agents, Phytogenic; Apoptosis; Blast Crisis; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Female; Harringtonines; Hematopoietic Stem Cells; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male	1997
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation. Blood, 1997, Jun-15, Volume: 89, Issue:12 Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Remission Induction; Transplantation, Autologous; Vincristine	1997
Early transformation to acute myeloblastic leukaemia with the acquisition of inv(16) in Ph positive chronic granulocytic leukaemia. Leukemia research, 1997, Volume: 21, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Chromosome Inversion; Chromosome Mapping; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Fatal Outcome; Humans; Idarubicin; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Philadelphia Chromosome	1997
Optimizing treatment for chronic myeloid leukemia. The New England journal of medicine, 1997, Jul-24, Volume: 337, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recombinant Proteins	1997
Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. International journal of dermatology, 1997, Volume: 36, Issue:8 Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Erythema; Female; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence	1997
Mobilization of hematopoietic progenitors in patients with chronic myeloid leukemia. Bone marrow transplantation, 1997, Volume: 20, Issue:10 Topics: Adult; Clone Cells; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Female; Filgrastim; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Polymerase Chain Reaction; Recombinant Proteins; RNA, Messenger; RNA, Neoplasm; Tumor Stem Cell Assay	1997
Interferon alfa-2b and cytarabine in chronic myelogenous leukemia. The New England journal of medicine, 1997, Nov-27, Volume: 337, Issue:22 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recombinant Proteins	1997
Linear chronic cutaneous graft-versus-host disease. Journal of the American Academy of Dermatology, 1997, Volume: 37, Issue:6 Topics: Adult; Basement Membrane; Bone Marrow Transplantation; Chronic Disease; Cyclosporine; Cytarabine; E-Selectin; Epidermis; Graft vs Host Disease; Humans; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Keratosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Methotrexate; Platelet Endothelial Cell Adhesion Molecule-1; Transplantation, Homologous; Whole-Body Irradiation	1997
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood, 1998, Mar-01, Volume: 91, Issue:5 Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cysteine Endopeptidases; Cytarabine; Cytochrome c Group; Enzyme Activation; Etoposide; Fusion Proteins, bcr-abl; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sphingolipids; Transfection; Tumor Cells, Cultured	1998
Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. American journal of hematology, 1998, Volume: 57, Issue:4 Topics: Adult; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Female; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Neoplasm, Residual; Recombinant Proteins	1998
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha. British journal of haematology, 1998, Volume: 101, Issue:1 Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome	1998
Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood, 1998, Sep-01, Volume: 92, Issue:5 Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Transplantation Conditioning; Transplantation, Autologous	1998
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia. Leukemia research, 1998, Volume: 22, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Retrospective Studies; Survival Rate	1998
[Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1998, Volume: 39, Issue:12 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Clone Cells; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Survivors	1998
Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase. Haematologica, 1999, Volume: 84, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Tretinoin	1999
[Interferon-alpha in the treatment of chronic myeloid leukemia]. La Revue du praticien, 1999, Mar-01, Volume: 49, Issue:5 Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Cause of Death; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome	1999
Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leukemia & lymphoma, 1999, Volume: 34, Issue:5-6 Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Genes, abl; Humans; In Situ Hybridization, Fluorescence; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins; Philadelphia Chromosome; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Recombinant Proteins; Sensitivity and Specificity; Translocation, Genetic	1999
Characterisation of the differential response of normal and CML haemopoietic progenitor cells to macrophage inflammatory protein-1alpha. Leukemia, 1999, Volume: 13, Issue:12 Topics: Adolescent; Adult; Aged; Cell Adhesion; Cell Cycle; Chemokine CCL3; Chemokine CCL4; Child; Cytarabine; Female; Fluorescent Antibody Technique; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophage Inflammatory Proteins; Male; Middle Aged; Neoplastic Stem Cells; Receptors, CCR5; Tumor Necrosis Factor-alpha	1999
Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:1 Topics: Aged; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease-Free Survival; Humans; Hydroxyurea; Interferon Type I; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Prognosis; Recombinant Proteins; Survival Rate; Time Factors	2000
Mini-ICE regimen allows mobilization of peripheral blood progenitor cells in a patient with chronic myelogenous leukemia failing the ICE protocol. Haematologica, 2000, Volume: 85, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Ifosfamide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male	2000
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cohort Studies; Cytarabine; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Mental Disorders; Middle Aged; Multivariate Analysis; Neurotoxicity Syndromes; Recombinant Proteins; Regression Analysis; Risk Factors	2000
Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy. Bone marrow transplantation, 2000, Volume: 25, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Cells; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Genes, abl; Humans; Interferon alpha-2; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recombinant Proteins; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transcription, Genetic; Transplantation, Autologous	2000
The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro. Haematologica, 2000, Volume: 85, Issue:6 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred Strains; Stem Cells; Tumor Cells, Cultured	2000
Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM. Leukemia, 2000, Volume: 14, Issue:8 Topics: Cell Division; Cytarabine; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tretinoin	2000
Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG). European journal of haematology, 2000, Volume: 64, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Vidarabine	2000
[Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia]. Casopis lekaru ceskych, 2000, Jul-19, Volume: 139, Issue:14 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome	2000
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside. Acta haematologica, 2000, Volume: 104, Issue:2-3 Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Differentiation; Cell Separation; Cytarabine; DNA Fragmentation; Electrophoresis, Agar Gel; Female; Granulocytes; Humans; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Macrophage-1 Antigen; Male; Middle Aged; Sialic Acid Binding Ig-like Lectin 3; Tretinoin; Tumor Cells, Cultured	2000
PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCR. Transfusion, 2001, Volume: 41, Issue:1 Topics: Adult; Cell Nucleus; Chronic Disease; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Interphase; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr	2001
Successful engraftment of allogeneic peripheral blood stem cell transplant after nonmyeloablative preparative regimen with cytarabine and cyclophosphamide: report of 2 cases. International journal of hematology, 2000, Volume: 72, Issue:4 Topics: Cyclophosphamide; Cytarabine; Graft Survival; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous	2000
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 2001, Apr-01, Volume: 97, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Microbial Sensitivity Tests; Neoplasm Proteins; Neoplasms; Piperazines; Pyrimidines; Tumor Cells, Cultured; Vincristine	2001
[Low-dose cytosine-arabinoside (Ara-C) therapy for chronic myeloid leukemia]. Voprosy onkologii, 2001, Volume: 47, Issue:1 Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Time Factors; Treatment Outcome	2001
Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia. Leukemia & lymphoma, 2001, Volume: 41, Issue:1-2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Decision Trees; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Markov Chains; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2001
Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages. Acta haematologica, 2001, Volume: 106, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Caspase 14; Caspases; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Recombinant Proteins; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2001
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. British journal of haematology, 2001, Volume: 115, Issue:1 Topics: Adult; Aged; Antigens, CD34; Busulfan; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine	2001
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient. Bone marrow transplantation, 2001, Volume: 28, Issue:8 Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Combined Modality Therapy; Cyclosporine; Cytarabine; Cytomegalovirus Infections; Cytosine; Drug Resistance, Viral; Fatal Outcome; Foscarnet; Graft vs Host Disease; Herpes Genitalis; Herpes Simplex; Humans; Hydroxyurea; Immunocompromised Host; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Simplexvirus; Transplantation Conditioning; Whole-Body Irradiation	2001
Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. Haematologica, 2002, Volume: 87, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component Removal; Bone Marrow Purging; Busulfan; Cytarabine; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Hydroxyurea; Immunologic Factors; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Neoplastic Cells, Circulating; Pain; Philadelphia Chromosome; Recombinant Proteins; Remission Induction; Safety; Transplantation, Autologous; Treatment Outcome	2002
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. British journal of haematology, 2002, Volume: 116, Issue:1 Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzamides; Cell Division; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cells; Tretinoin; Tyrphostins	2002
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. British journal of cancer, 2002, May-06, Volume: 86, Issue:9 Topics: Antineoplastic Agents; Benzamides; Cell Death; Cytarabine; Enzyme Inhibitors; Etoposide; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured	2002
Not so NICE for CML. Lancet (London, England), 2002, Jun-08, Volume: 359, Issue:9322 Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Approval; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome	2002
Cytomegalovirus infection in children with blood diseases. Acta haematologica Polonica, 1992, Volume: 23, Issue:3 Topics: Adolescent; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Daunorubicin; Female; gamma-Globulins; Humans; Immune Tolerance; Immunization, Passive; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Opportunistic Infections; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Thioguanine; Vincristine	1992
[Treatment of leukemia: discussion]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1992, Jul-10, Volume: 81, Issue:7 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Hematologic Tests; Humans; L-Lactate Dehydrogenase; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mercaptopurine; Prednisolone; Remission Induction	1992
Cytarabine and cardiac failure. American journal of hematology, 1992, Volume: 41, Issue:2 Topics: Adult; Cytarabine; Female; Heart Failure; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive	1992
[Treatment of CML with blastic crisis by the combination therapy of VP and low-dose Ara-C]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1992, Volume: 33, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prednisolone; Vincristine	1992
Disappearance of a highly unusual clone, 46,XY,del(7)(p12),t(9;22)(q34;q11) in chronic myeloid leukemia after treatment with recombinant interferon and cytosine arabinoside. Cancer genetics and cytogenetics, 1992, Volume: 64, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Gene Deletion; Humans; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Recombinant Proteins; Translocation, Genetic	1992
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Research Design; Survival Analysis; Treatment Outcome	1992
Leukemia following cisplatin-based chemotherapy for ovarian carcinoma at Roswell Park. European journal of gynaecological oncology, 1992, Volume: 13, Issue:2 Topics: Adult; Carcinoma, Papillary; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Neoplasms, Second Primary; Ovarian Neoplasms; Thrombocytopenia	1992
Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response. Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arabinofuranosyluracil; Cytarabine; Deamination; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Serum Albumin, Bovine; Sex Factors	1992
Multiparameter assessment of the cell cycle effects of bioactive and cytotoxic agents. Cancer research, 1992, Aug-01, Volume: 52, Issue:15 Topics: Animals; Bone Marrow; Bromodeoxyuridine; Cell Cycle; Cell Nucleus; Cell Survival; Cells, Cultured; Chickens; Cytarabine; DNA Replication; DNA, Neoplasm; G1 Phase; G2 Phase; Interferon alpha-2; Interferon-alpha; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mitosis; Propidium; Recombinant Proteins; S Phase; Tretinoin; Tumor Cells, Cultured	1992
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Diseases; Cytarabine; Daunorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Middle Aged; Prognosis; Remission Induction; Survival Analysis	1992
Inhibition by 1,25 dihydroxyvitamin D3 of chemically induced erythroid differentiation of K562 leukemia cells. Blood, 1991, Apr-01, Volume: 77, Issue:7 Topics: Animals; Calcitriol; Cell Differentiation; Cell Division; Cell Line; Cytarabine; Humans; Kinetics; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Receptors, Calcitriol; Receptors, Steroid; Ribavirin; RNA, Messenger; Time Factors	1991
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 1991, Sep-15, Volume: 68, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Drug Resistance; Female; Follow-Up Studies; Humans; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pilot Projects; Prednisone; Survival Rate; Vincristine	1991
Interferon alpha in the therapy of CML. British journal of haematology, 1991, Volume: 79 Suppl 1 Topics: Combined Modality Therapy; Cytarabine; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recombinant Proteins	1991
High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia. American journal of clinical oncology, 1991, Volume: 14, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate	1991
Erythroid differentiation of K-562 cells induced by ethidium bromide. Leukemia research, 1991, Volume: 15, Issue:5 Topics: Acridine Orange; Cell Differentiation; Cell Line; Cytarabine; Dimethyl Sulfoxide; DNA Polymerase II; Ethidium; Ethionine; Hemoglobins; Humans; Intercalating Agents; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polynucleotide Adenylyltransferase	1991
Structure-activity relationships of cadeguomycin analogs. The Journal of antibiotics, 1991, Volume: 44, Issue:6 Topics: Anti-Bacterial Agents; Cell Count; Cell Division; Cytarabine; Cytosine Nucleotides; Drug Synergism; Guanosine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Structure-Activity Relationship; Tumor Cells, Cultured	1991
Acute tumor lysis syndrome in a patient with chronic myelogenous leukemia in blast crisis: role of high-dose Ara-C. Bone marrow transplantation, 1990, Volume: 6, Issue:4 Topics: Acute Disease; Adult; Blast Crisis; Bone Marrow Transplantation; Cytarabine; Dose-Response Relationship, Drug; Graft vs Host Disease; Humans; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Tumor Lysis Syndrome	1990
[Chronic granulocytic leukemia in childhood]. Revista clinica espanola, 1990, Volume: 187, Issue:6 Topics: Child; Combined Modality Therapy; Cytarabine; Female; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive	1990
Cytogenetics and molecular analysis in chronic myelogenous leukemia patients treated by interferon and chemotherapy. Nouvelle revue francaise d'hematologie, 1990, Volume: 32, Issue:5 Topics: Adult; Combined Modality Therapy; Cytarabine; Female; Humans; Hydroxyurea; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymerase Chain Reaction; Remission Induction	1990
Transcriptional regulation of c-jun gene expression by arabinofuranosylcytosine in human myeloid leukemia cells. The Journal of clinical investigation, 1990, Volume: 86, Issue:5 Topics: Actins; Blotting, Northern; Cell Cycle; Cell Differentiation; Cytarabine; Dactinomycin; DNA-Binding Proteins; Gene Expression Regulation; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Proto-Oncogenes; Tetradecanoylphorbol Acetate; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured	1990
Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM. Haematology and blood transfusion, 1990, Volume: 33 Topics: Cells, Cultured; Cytarabine; Drug Administration Schedule; Drug Synergism; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitoxantrone; Neoplastic Stem Cells; Tumor Cells, Cultured	1990
Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia. Haematology and blood transfusion, 1990, Volume: 33 Topics: Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Austria; Blast Crisis; Cytarabine; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma	1990
High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. European journal of haematology, 1990, Volume: 44, Issue:4 Topics: Adolescent; Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma	1990
Juvenile chronic myelocytic leukemia: experience with intensive combination chemotherapy. Medical and pediatric oncology, 1990, Volume: 18, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Daunorubicin; Discriminant Analysis; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Recurrence; Survival Rate	1990
Postoperative pulmonary leukostasis. Critical care medicine, 1990, Volume: 18, Issue:1 Topics: Aged; Allopurinol; Cytarabine; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Positive-Pressure Respiration; Postoperative Complications; Respiratory Insufficiency	1990
Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) is resistant to effective therapy for Ph1-negative ALL. Acta haematologica, 1989, Volume: 81, Issue:4 Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Potassium Chloride; Remission Induction; Time Factors	1989
Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside. Cancer immunology, immunotherapy : CII, 1989, Volume: 29, Issue:4 Topics: Antigens, Differentiation; Cytarabine; Cytotoxicity, Immunologic; Humans; Immunity, Cellular; Immunotherapy; In Vitro Techniques; Interleukin-2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; T-Lymphocytes; Tumor Cells, Cultured	1989
Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia, 1989, Volume: 3, Issue:5 Topics: Blast Crisis; Cell Division; Colony-Stimulating Factors; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Tumor Cells, Cultured	1989
Daunomycin, cytosin-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML. Blut, 1989, Volume: 58, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Thioguanine	1989
A study of the mechanisms of cytotoxicity of Ara-C on three human leukemic cell lines. Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:4 Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine Kinase; Deoxycytosine Nucleotides; DNA; DNA Ligases; DNA Polymerase II; DNA, Neoplasm; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured; Tumor Stem Cell Assay	1989
Combined therapy interferon and chemotherapy in chronic myelogenous leukemia. Nouvelle revue francaise d'hematologie, 1989, Volume: 31, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Drug Evaluation; Humans; Hydroxyurea; Interferon alpha-2; Interferon Type I; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Recombinant Proteins; Remission Induction	1989
Pretreatment of chronic myelogenous leukemic blood samples with cytosine arabinoside prior to mixed lymphocyte culture typing. Transplantation, 1988, Volume: 46, Issue:4 Topics: Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Culture Test, Mixed; Premedication	1988
[BH-AC.AMP protocol in the treatment of refractory childhood acute leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:10 Topics: Aclarubicin; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Female; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma; Male; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction	1988
Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. American journal of clinical oncology, 1988, Volume: 11, Issue:6 Topics: Adult; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged	1988
Acute acquired demyelinating polyneuropathy with respiratory failure following high-dose systemic cytosine arabinoside and marrow transplantation. Bone marrow transplantation, 1987, Volume: 2, Issue:2 Topics: Adult; Bone Marrow Transplantation; Cytarabine; Demyelinating Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Polyradiculoneuropathy	1987